Malaria Clinical Trial - Malaria Survey in Mbarara District, Uganda 2010

Status Completed

Clinical Trial Summary

Malaria is one of the major public health problems in Sub-Saharan Africa. In response to this threat, Roll Back Malaria (RBM) has rolled back a strategy using ACT as first line therapy for malaria episode, a wide distribution of Insecticide Treated Bednet (ITN), intermittent presumptive treatment of pregnant women and indoor residual spraying. Recent epidemiological observations suggested a decline in malaria prevalence in some countries but further evidences are still needed to confirm this evolution. The RBM strategy requires the use of reliable rapid diagnostic test (RDT) for which an operational assessment is necessary. Lastly, home-based management of malaria is also an important compound of this strategy. However, a better understanding of the actual use of antimalarial drugs, of the use of bednet and of the barrier to the use of health care is important to implement good quality strategies for malaria control.

This study is a cross-sectional community based survey made of two rounds (one in January 2010 and the second in June 2010). The general objective is to measure the prevalence of infection with Plasmodium falciparum at two periods of the year (at the moment of lowest and highest transmission based on the seasonal rainfalls) and to compare it with the prevalence estimated in 2004 after the rainy season for the same area. Specific objective are the estimation of the prevalence by age stratum, the analysis of the geographical distribution of the infection, the description of the parasitological characteristics, the assessment of three RDT, the description and the analysis of the prevention and care seek behaviours related to malaria.

The study area is the great Mbarara district located in south-west of Uganda. A three-stage cluster sampling method will be used. Spatial information will be collected with global positioning system and imported to Geographical Information System. Behaviour information will be collected through face to face interview.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Malaria

Clinical Trial Details

NCT number	NCT01062386
Study type	Observational
Source	Epicentre
Contact
Status	Completed
Phase	N/A
Start date	January 2010
Completion date	July 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04601714` - Baseline Cohort Malaria Morbidity Study
Withdrawn	`NCT04020653` - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria	Phase 2
Terminated	`NCT04368910` - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria	Phase 3
Completed	`NCT03641339` - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans	N/A
Completed	`NCT02544048` - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed	`NCT00527163` - Role of Nitric Oxide in Malaria
Not yet recruiting	`NCT05934318` - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)	N/A
Active, not recruiting	`NCT04704674` - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed	`NCT03276962` - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age	Phase 2
Completed	`NCT04966871` - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults	Phase 1
Completed	`NCT00289185` - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants	Phase 2
Recruiting	`NCT03937817` - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting	`NCT06153862` - Africa Ready Malaria Screening	N/A
Completed	`NCT04545905` - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting	`NCT06278181` - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Withdrawn	`NCT02793414` - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Completed	`NCT02909712` - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania	Phase 2
Completed	`NCT02793622` - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants	Phase 3
Withdrawn	`NCT02793388` - A Trial on Supervised Primaquine Use in Ethiopia	Phase 4
Completed	`NCT02605720` - Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.